<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117490">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679769</url>
  </required_header>
  <id_info>
    <org_study_id>2012-455</org_study_id>
    <secondary_id>81170386</secondary_id>
    <nct_id>NCT01679769</nct_id>
  </id_info>
  <brief_title>Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B</brief_title>
  <official_title>Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and
      radiology methods in patients with chronic hepatitis B in mainland China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>Quality of staging fibrosis with a combination of non-invasive parameters compared to liver biopsy</measure>
    <time_frame>singular evaluation at the time of liver biopsy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of staging inflammation with a combination of non-invasive parameters compared to liver biopsy</measure>
    <time_frame>singular evaluation at the time of liver biopsy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      liver biopsy samples and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic hepatitis B or compensated cirrhosis due to chronic hepatits B virus
        (HBV) infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of chronic hepatitis B or compensated cirrhosis due to chronic
             hepatitis B virus infection

          -  agree to have liver biopsy

        Exclusion Criteria:

          -  clinical diagnosis of decompensated cirrhosis due to hepatitis B virus or inactive
             carrier

          -  liver diseases due to other origin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hong zhao, MD</last_name>
    <phone>13810765943</phone>
    <email>minmin2001@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guiqiang Wang, MD</last_name>
    <phone>13911405123</phone>
    <email>john131212@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Bei Jing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Wang</last_name>
      <phone>86-10-66551211</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>September 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guiqiang Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
